Glioma Diagnosis and Treatment
Glioma Diagnosis and Treatment is a research topic within Genetics. Science Explorer counts 66k research works in it since 1950. 14.7% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the genetics, classification, treatment, and epidemiology of gliomas, particularly glioblastoma and medulloblastoma. It covers topics such as the molecular pathways, mutations (e.g., IDH), treatment strategies (e.g., temozolomide, radiotherapy), and the use of immunotherapy in neuro-oncology.
- Glioblastoma
- Temozolomide
- IDH Mutation
- Radiotherapy
- Molecular Classification
- MGMT Promoter Methylation
- Medulloblastoma
- Brain Tumor Epidemiology
- Immunotherapy
- Neuro-Oncology
- Research works
- 66k fractional, since 1950
- In the world top 10%
- 9.7k per year above
- Top-10% rate
- 14.7% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +36% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Glioma Diagnosis and Treatment research?
By volume, the United States and China publish the most (4.2k and 2.2k works in 2022–2025).
By volume, 2022–2025
- 1 United States 4.2k works
- 2 China 2.2k works
- 3 Germany 862 works
- 4 Japan 669 works
- 5 India 658 works
- 6 Italy 591 works
- 7 United Kingdom 557 works
- 8 France 415 works
- 9 Canada 377 works
- 10 South Korea 269 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Glioma Diagnosis and Treatment research?
By volume in 2022–2025, Neurological Surgery publishes the most Glioma Diagnosis and Treatment research, followed by The University of Texas MD Anderson Cancer Center and Capital Medical University.
By volume, 2022–2025
- 1 Neurological SurgeryUnited States 115 works
- 2 The University of Texas MD Anderson Cancer CenterUnited States 103 works
- 3 Capital Medical UniversityChina 87 works
- 4 University of California, San FranciscoUnited States 83 works
- 5 Memorial Sloan Kettering Cancer CenterUnited States 62 works
- 6 Heidelberg UniversityGermany 61 works
- 7 Stanford UniversityUnited States 57 works
- 8 Harvard UniversityUnited States 53 works
- 9 Northwestern UniversityUnited States 53 works
- 10 University of MichiganUnited States 52 works
Who are the leading researchers in Glioma Diagnosis and Treatment?
The most-cited researchers publishing on Glioma Diagnosis and Treatment include Gad Getz.
- 1 Gad Getz United States 6.2k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Glioma Diagnosis and Treatment research done?
The largest centres of Glioma Diagnosis and Treatment research in 2022–2025 are Beijing (China), New York (United States), Guangzhou (China) and Boston (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Rockville Centre, Heidelberg and Phoenix.
Largest cities, 2022–2025
Where it is the local speciality
- Rockville CentreUS · 114.8 works57×
- HeidelbergDE · 192.6 works14×
- PhoenixUS · 46.9 works11×
Location quotient: how much more of its research is in Glioma Diagnosis and Treatment than the world average.
Where is the best place to study Glioma Diagnosis and Treatment?
Among universities, judged by research, Capital Medical University, University of California, San Francisco and Heidelberg University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Capital Medical UniversityChina | 61.6 | 15.6% | 10.9× | 86 | +67.5% |
| 2 | University of California, San FranciscoUnited States | 59.8 | 16.2% | 9.5× | 83 | +37.1% |
| 3 | Heidelberg UniversityGermany | 59.3 | 19.6% | 8.5× | 62 | +37.7% |
| 4 | Northwestern UniversityUnited States | 53.9 | 15.2% | 5.7× | 53 | +172.0% |
| 5 | Jacksonville CollegeUnited States | 52.1 | 26.2% | 8.8× | 9 | +116.6% |
| 6 | Vita-Salute San Raffaele UniversityItaly | 49.7 | 32.0% | 5.7× | 10 | +92.3% |
| 7 | University of ZurichSwitzerland | 49.4 | 26.0% | 2.8× | 21 | +171.5% |
| 8 | Harvard UniversityUnited States | 49.3 | 24.1% | 3.1× | 53 | +76.8% |
| 9 | Medical University of ViennaAustria | 48.3 | 14.4% | 8.1× | 34 | +5.7% |
| 10 | The University of Texas Health Science Center at HoustonUnited States | 48.3 | 17.1% | 5.2× | 21 | +240.2% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Glioma Diagnosis and Treatment research growing?
Output in 2018–2022 was 36% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Glioma Diagnosis and Treatment.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.